Victoza is a GLP-1 injectable manufactured by Novo Nordisk. It became a blockbuster drug after celebrity chef Paula Deen endorsed it as the medication that she used to control her type 2 diabetes. Novo Nordisk also touts the drug as one that will help patients lose weight, though it is not approved for weight loss. This makes it even more attractive to diabetes patients that also struggle to control their weight.
Unfortunately, Victoza has become known as a dangerous drug that could cause thyroid cancers and tumors, pancreatitis and pancreatic cancer, and kidney complications and failure. The drug has become so notorious that some consumer advocacy groups are calling for the FDA to remove Victoza from the market. While it has not taken such action, the FDA has required Novo Nordisk to add a black box warning to Victoza.
Have you taken Victoza and suffered serious side effects? We want to answer your questions. We hope you find the content presented here helpful and informative, and that you contact us so that we can discuss your specific case.
Novo Nordisk Seeks New Uses for Victoza
Novo Nordisk’s Chief Science Officer Mads Krogsgaard Thomsen stated that the pharmaceutical company is looking into continuing trials to determine if Victoza could be marketed as a possible Alzheimer’s treatment. Victoza is currently going through a proof of concept study. If this is successful, the drug will continue through phase III clinical trials to see…
Incretin Mimetic Drug Lawsuits Consolidated in Federal Court
On August 28, 2013, it was announced that litigation involving incretin mimetic drugs Byetta, Victoza, Januvia, and Janumet are being consolidated into multi-district litigation in California federal court. Usually lawsuits against different companies, as is in this case, are not consolidated into one MDL. In this case however, many of the plaintiffs bringing the lawsuits…
Novo Nordisk Looking To Get Victoza Approved for Weight Loss
In April 2013, results from Novo Nordisk’s clinical trial of diabetes drug Victoza showed that the drug can help obese people lose weight. The FDA has not yet granted Novo Nordisk approval for this indication, but with further studies planned, they hope to do so soon. Both diabetes and insulin can cause weight gain,…